Deals
Teva Europe Portfolio Said to Draw Interest From Mylan, Novartis
- Teva’s portfolio could fetch $1.5 billion to $2 billion
- Private equity firms also weighing offers for the business
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd.’s portfolio of drugs in the U.K., Ireland and Iceland is attracting bidders including Mylan NV and Novartis AG, people familiar with the matter said.
Private equity firms including Apollo Global Management LLC and Cinven Ltd. are also weighing bids for the business, which could fetch $1.5 billion to $2 billion, the people said, asking not to be named because the deliberations are private. The European Commission would prefer that the assets go to a strategic buyer with experience in the European generics market, the people said.